SOPHiA GENETICS (NASDAQ:SOPH) Price Target Raised to $14.00

SOPHiA GENETICS (NASDAQ:SOPH) had its target price boosted by equities research analysts at HC Wainwright from $12.00 to $14.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 104.68% from the company’s previous close.

Several other research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Stock Up 20.2%

Shares of NASDAQ:SOPH opened at $6.84 on Wednesday. The business has a fifty day simple moving average of $5.52 and a 200 day simple moving average of $5.11. SOPHiA GENETICS has a 12-month low of $2.92 and a 12-month high of $6.98. The firm has a market cap of $573.81 million, a P/E ratio of -13.15 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. Analysts predict that SOPHiA GENETICS will post -0.58 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the transaction, the insider owned 614,887 shares of the company’s stock, valued at approximately $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jurgi Camblong sold 50,069 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the transaction, the chief executive officer directly owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. This represents a 1.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 221,092 shares of company stock valued at $1,250,070 over the last three months. Insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of large investors have recently added to or reduced their stakes in SOPH. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $49,000. Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the 1st quarter worth approximately $50,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Raised 2026 outlook: SOPHiA GENETICS increased its full-year revenue guidance to $94 million-$96 million, representing 22%-24% year-over-year growth and exceeding the approximately $93.4 million analyst consensus. Management also expects to reach adjusted EBITDA breakeven by year-end, an important milestone for the currently loss-making company. SOPHiA GENETICS 2026 outlook
• Positive Sentiment: Revenue beat and improving EBITDA: Second-quarter revenue rose 27% year over year to $23.3 million, ahead of the $21.7 million consensus estimate. The adjusted EBITDA loss narrowed 27% to $8.8 million, indicating progress toward profitability. SOPHiA GENETICS Q2 2026 results
• Positive Sentiment: AstraZeneca partnership: The company entered a multiyear global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision-oncology therapies. The agreement could expand SOPHiA’s role in pharmaceutical development and commercial testing, although financial terms were not disclosed. SOPHiA GENETICS AstraZeneca collaboration
• Negative Sentiment: Bottom-line miss: SOPHiA GENETICS reported a second-quarter loss of $0.26 per share, worse than the $0.21 consensus estimate. Net loss remained elevated at $22.4 million, while reported and adjusted gross margins declined from the prior-year period. SOPHiA GENETICS earnings report

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.